GSK plc (LON:GSK)
1,396.50
+25.00 (1.82%)
Jul 24, 2025, 3:45 PM BST
GSK plc Revenue
GSK plc had revenue of 7.52B GBP in the quarter ending March 31, 2025, with 2.08% growth. This brings the company's revenue in the last twelve months to 31.53B, up 2.57% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.53B
Revenue Growth
+2.57%
P/S Ratio
1.76
Revenue / Employee
459.41K
Employees
68,629
Market Cap
55.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Genus | 671.60M |
GSK plc News
- 21 hours ago - GSK gets extended review for blood cancer drug in U.S. despite negative AdCom vote - Seeking Alpha
- 22 hours ago - US FDA extends review of GSK's blood cancer drug - Reuters
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 5 days ago - European Stocks Post Small Weekly Drop; GSK Weighs on Healthcare - Financial Post
- 5 days ago - Global Stocks Recap: Alibaba, Saab, Burberry, GSK - The Wall Street Journal
- 6 days ago - GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt - WSJ
- 6 days ago - GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning - Benzinga
- 6 days ago - GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive - Investomania